Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BARCELONA, Spain--(BUSINESS WIRE)--Flat Footed LLC is the investment manager for FF Hybrid LP, Flat Footed Series LLC - Fund 3, and GP Recovery Fund LLC (collectively, with Flat Footed LLC, “Flat Footed”), holders of an aggregate 4.64% of the voting share capital of Grifols, S.A. (the “Grifols” or the “Company”). Flat Footed today sent a letter to the Grifols Board of Directors. The full text of the letter follows: Dear Mr. Glanzmann, Flat Footed LLC is the investment manager for FF Hybrid LP,.

Flat Footed Calls for Prompt Governance Overhaul at Grifols

The outgoing head of Spain's stock market regulator CNMV, Rodrigo Buenaventura, told reporters on Thursday that there were signs of possible market manipulation in the dispute between short seller Gotham City Research and pharma company Grifols.

Spain's market regulator sees signs of manipulation in Grifols-Gotham dispute

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”) requesting the disclosure of important information regarding Tomas Daga, a nearly 25-year member of the Board and the Grifols family's closest advisor, so that Grifols shareholders have a better u.

Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga

MADRID--(BUSINESS WIRE)--Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the “Clients”) holding in aggregate 5.65% of A shares and 3.88% of B shares (including ADRs) in Grifols, S.A. (“Grifols” or the “Company”). As of 29 November 2024 closing prices, the Clients' aggregate stake in Grifols is valued at €275 million. The Clients thank the Transaction Committee for its wholehearted engagement with Brookfield and strongly support the decisi.

Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols

I don't divest unless the fundamental thesis changes; Grifols' buyout offer from Brookfield Asset Management is undervalued, so I maintain my "Buy" stance. Despite Brookfield's offer, I believe Grifols is worth more, as supported by recent 3Q24 results and the transaction committee's recommendation. The transaction committee advises against accepting the €10.5/share offer, aligning with my view that Grifols' real value is higher.

Grifols: More Attractive Than In A Very Long Time

On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.

Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.

Grifols Stock Declines After Brookfield Drops Buyout Offer

Shares in Grifols were falling on Wednesday morning after Bloomberg reported Canadian fund Brookfield is considering dropping its plan to take over the Spanish pharmaceutical firm.

Grifols shares tumble after report on Brookfield abandoning takeover plan

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer significantly undervalued the Spanish drugmaker's prospects and long-term potential.

Grifols: Brookfields potential $6.8 bln offer undervalues the firm

An investigating magistrate at the Spanish High Court said on Tuesday it had opened an investigation into U.S.-based short seller Gotham City's actions that brought down the share price of Spanish pharmaceutical firm Grifols in January.

Spanish court opens investigation into Gotham City's attack on Grifols

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”). In the letter, Mason reiterated the Company's corporate governance deficiencies, which have inflicted large losses on all shareholders and resulted in a rumored take-private by affiliates of Broo.

Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors

Canadian fund Brookfield plans to offer about 7 billion euros ($7.4 billion) for Spanish drugmaker Grifols after finishing due diligence, news website El Confidencial reported on Monday, citing sources close to the matter.

Brookfield mulls $7.4 bln bid for Spain's Grifols, El Confidencial says

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”). In the letter, Mason highlights numerous corporate governance failures that have resulted in Grifols' depressed share price and a rumored transaction with affiliates of Brookfield Asset Managemen.

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the same period a year ago.

Grifols on track to meet 2024 targets despite third-quarter profit drop

Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, with impressive 2024 earnings forecasts and improving margins and leverage.

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down

Spanish drugmaker Grifols plans to invest 360 million euros ($401.98 million) to build a new industrial plant in Barcelona for its engineering department, newspaper El Economista said on Monday, citing unidentified company sources.

Grifols plans to invest $402 million in new industrial centre, El Economista says

BARCELONA, Spain--(BUSINESS WIRE)--Significant Grifols shareholders fill a vacant board seat, appointing pharma leader Paul Herendeen to drive value and improve governance.

Significant Shareholders Exercise Right to Grifols Board Seat

CAIRO--(BUSINESS WIRE)--Orange Business is pleased to announce the successful completion of the first phase of a new data center and communications infrastructure for Grifols Egypt for its Plasma Derivatives (GEPD) facility in the Medical City within the New Administrative Capital. The partnership involves delivering co-location services through the ACUD (Administrative Capital for Urban Development) commercial and telco data center. This includes communication services, support in equipment pr.

Grifols Egypt Collaborates with Orange Business to Deliver New Data Center and Communications Infrastructure, Supporting Advanced Medical Processes

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Is Looking Into Grifols SA For Possible Securities Related Improprieties And Stockholders Are Invited To Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Grifols S.A. May Have Committed Fraud And Investors Are Urged To Contact The Schall Law Firm About An Inquiry

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Is Looking Into Grifols SA For Possibly Violating Securities Laws And Stakeholders Are Invited To Partake In The Investigation

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Grifols SA May Have Committed Securities Fraud And Investors With Losses Should Join The Schall Law Firm's Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

An Investigation Has Been Launched By The Schall Law Firm Into Grifols S.A.'s Possible Securities Law Violations And Shareholders Can Join

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

News for Grifols, S.A. Stock (GRFS)